Results 101 to 110 of about 22,968 (195)

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Experimental Hematology & Oncology
Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its ...
Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener   +18 more
doaj   +1 more source

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Journal of Global Oncology, 2019
PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer.
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, Ave Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi   +15 more
doaj   +1 more source

Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer [PDF]

, 2018
Cyclin-dependent kinase (CDK) 4/6 inhibition has been demonstrated to improve progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2−), hormone receptor positive (HR+) in advanced breast cancer [1–3]. Palbociclib,
Abbosh, C, Birkbak, NJ, Swanton, C
core  

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Cell Death Discovery
Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation.
Cui Chen, Zehong Chen, Jinze Zhao, Xinyun Wen, Hanming Yao, Zijin Weng, Huiping Xiong, Zongheng Zheng, Juekun Wu   +8 more
doaj   +1 more source

Palbociclib-Induced Liver Failure [PDF]

, 2020
Atallah, Rami, Dingwall, Megan, Hamouche, Karl, Parker, Nathaniel, Truong, Quoc   +4 more
core   +2 more sources

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors

Pharmaceutics
Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors ...
John C. Panetta, Nicholas S. Selvo, David Van Mater, Clinton F. Stewart   +3 more
doaj   +1 more source

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

Breast Cancer Research
Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways.
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene   +7 more
doaj   +1 more source

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

Cancer Management and Research, 2018
Daniel J Asby,1 Clare L Killick-Cole,1 Lisa J Boulter,1 William GB Singleton,1,2 Claire A Asby,3 Marcella J Wyatt,1 Neil U Barua,1,2 Alison S Bienemann,1 Steven S Gill1,2 1Functional Neurosurgery Research Group, Translational Health Sciences, Bristol ...
Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WGB, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS   +8 more
doaj  

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Cancer Medicine
Introduction Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the current standard of care for first‐line (1L) treatment of hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR ...
Adam M. Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth, Benjamin Li, Elizabeth Esterberg, Doris Makari, Sean D. Candrilli, Ravi K. Goyal, Hope S. Rugo   +10 more
doaj   +1 more source

In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments

Drug Design, Development and Therapy
Wenyu Du,1,2 Zihan Liu,1,2,* Ying Li,2,* Zhi Wang,2 Zhanjun Dong2 1Graduate School, Hebei Medical University, Shijiazhuang, 050017, People’s Republic of China; 2Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy ...
Du W, Liu Z, Li Y, Wang Z, Dong Z
doaj